# US 2012/0083505 A1 · Use of opioid receptor antagonists for acute treatment of paraphilic arousal states

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083505 A1
- Document ID: US20120083505A1
- Status: Published application
- Kind: A1
- Application number: 13/377,554
- Filed: 2010-06-08
- Published: 2012-04-05
- Earliest claimed: 2009-06-11
- Inventors: Klaus M Beier; Michael Dittgen; Eike Dittgen; Alfred Pauls
- Web page: https://patentgrep.com/patent/US20120083505A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to an opioid receptor antagonist or a pharmaceutically acceptable salt thereof for use in a method of acute treatment of paraphilic sexual arousal states in patients suffering from paraphilia.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

Method of acute treatment of a paraphilic sexual arousal state, comprising administering an effective dose of an opioid receptor antagonist or a pharmaceutically acceptable salt thereof to a patient suffering from a paraphilia, wherein the opioid receptor antagonist is a 3,14-dihydroxy-4,5-epoxymorphinan-6-on compound in which the hydrogen of N at position 17 is substituted by a methyl, ethyl, propyl, butyl, isobutyl, cyclopropylmethyl, allyl, benzyl or phenethyl group.

### Claim 17 (depends on 16)

Method of claim 16, characterized in that the acute treatment is a self-administration by the patient of the opioid receptor antagonist or the pharmaceutically acceptable salt thereof, wherein each self-administration is directly triggered upon self-perception by the patient of presence or reasoned expectance of the onset of a particular paraphilic sexual arousal state.

### Claim 18 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist is Naloxon and/or Naltrexon.

### Claim 19 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered at a dose of not more than 5 mg/kg body weight per administration cycle.

### Claim 20 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered in a formulation for immediate release of the opioid receptor antagonist.

### Claim 21 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered in a formulation comprising 0.5 Mol/kg of a neutral and/or anionic macromolecule.

### Claim 22 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered orally, transdermally, nasally and/or mucosally.

### Claim 23 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered in form of a tablet, a capsule, a liquid, a powder, a lozenge, a wafer, a transmucosal therapeutic system, a nasal spray and/or an aerosol.

### Claim 24 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered to a patient suffering from paraphilia at the onset of or during an acute paraphilic sexual arousal state.

### Claim 25 (depends on 16)

Method of claim 16, wherein the opioid receptor antagonist or a pharmaceutically acceptable salt thereof is administered to a patient suffering from paraphilia directly before the patient is exposed to a situation, subject or subject matter suitable to elicit a paraphilic sexual arousal state of said patient.

### Claim 26 (depends on 16)

Method of claim 16, wherein more than one opioid receptor antagonist or a pharmaceutically acceptable salt thereof is used for acute treatment of paraphilic sexual arousal states.

### Claim 27 (depends on 16)

Method of claim 16, wherein the paraphilia is exhibitionism, fetishism, frotteurism, paedophilia, sexual masochism, sexual sadism, voyeurism, transvestic fetishism, telephone scatalogia, necrophilia, partialism, zoophilia, coprophilia, klismaphilia, urophilia and/or emetophilia

### Claim 28 (depends on 16)

Method of claim 16, wherein the paraphilia is paedophilia.
